

Calls for Expressions of Interest

ARTnet CORE IMAGING LABORATORY FACILITY

The Australasian Radiopharmaceutical Trials Network (ARTnet) was established in 2014 and is a joint initiative of Australasian Association of Nuclear Medicine Specialists and Australian and New Zealand Society of Nuclear Medicine. ARTnet aims to facilitate multicentre clinical trials in Australia utilising radiopharmaceuticals for imaging or therapy. A key role is providing support to ensure quality aspects of clinical trials utilising radiopharmaceuticals, including camera validation as part of a site initiation program.

Expressions of interest are sought from organisations or individuals to provide image analysis services to ARTnet that lead to site initiation for gamma cameras (planar), SPECT or PET imaging systems. The successful applicant(s) would receive data from ARTnet and provide analysis services to validate potential sites.

The scope of the analysis would involve verification of the image data supplied and computing quantitative measures, such as the SUV (Standardised Uptake Value) for tomographic emission images (SPECT and PET). The successful core lab should have the capacity to provide up to 50 site validations per annum. Site validation would not normally involve a representative of the core laboratory to visit the site unless requested by the trial or the site.

The Eoi should contain the following information:

- i) names of the individual(s) applying
- ii) core laboratory site details (address, environment, e.g., university, hospital, hardware and software systems used, etc)
- iii) qualifications of the core staff
- iv) experience in performing similar site initiations
- v) description of how the core lab aligns with ARTnet's mission statement and vision
- vi) specification of core lab capability including (provide detail on these processes)
 - camera validation and/or harmonisation
 - body, brain or other
 - PET, SPECT, CT and planar
 - range of radioisotopes supported by core lab capability
- vii) description of supporting documentation such as SOPs/manuals/instructions for sites, and supporting information for core lab analysis and report outputs
- viii) an indicative budget for site initiations for SPECT and PET systems, including phantom requirements and specifications
- ix) any other information relevant to this process.

www.ARTnet.org.au



The initial appointment would be for 24 months commencing in 2022, but would be renewable, subject to mutual agreement from both parties, to an extension for a further 12-24 months. Negotiation with the preferred core lab applicant will occur following submission of the EoI. ARTnet may appoint more than one core lab, depending on clinical trial requirements and scope of the core lab.

EoIs can be sent to, or any further information obtained from, the ARTnet Scientific Committee Chair scientific.chair@artnet.org.au

Closing Date: 10am on Monday October 18th, 2021.

www.ARTnet.org.au

The Australasian Radiopharmaceutical Trials Network is a collaboration of the

Australasian Association of Nuclear Medicine Specialists (AANMS)
PO Box 73 Balmain NSW 2041 | T +61.2.98184824 | F +61.2.9818 4806
E research@aanms.org.au

*and
the*

Australian and New Zealand Society of Nuclear Medicine (ANZSNM)
PO Box 6178 Vermont South Vic 3133 | T +61 1300 330 402 | F+61.3.8677 2970
E secretariat@anzsnm.org.au